Cabozantinib (BMS-907351)

For research use only.

Catalog No.S1119 Synonyms: XL184

86 publications

Cabozantinib (BMS-907351) Chemical Structure

CAS No. 849217-68-1

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 470 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cabozantinib (BMS-907351) has been cited by 86 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Targets
VEGFR2/KDR [1]
(Cell-free assay)
c-Met [1]
(Cell-free assay)
Axl [1]
(Cell-free assay)
0.035 nM 1.3 nM 7 nM
In vitro

XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
E98NT  NWHxN5RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMlAyNTFyIN88US=> MmXLSG1UVw>? NULBbodKUUN3ME24PUBvVQ>? NUXtPWxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PFQxODZpPkKzOFg1ODB4PD;hQi=>
SNU-5  MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn5OIJUUUN3ME2gNVkhdk1? NInLWpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
Hs746T  NF6xZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC3TWM2OD17Lkmgcm0> NWK1d29YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
SNU-1  MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPLXHpKSzVyPUWyNlMhdk1? M1rXd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
SNU-16 NYXZNIx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFzNEmgcm0> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
MDA-MB-231 NF74WlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILa[3pKSzVyPTC2OFIyKG6P MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
U87MG NUL2d|dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e4TWlEPTB;MUi1NUBvVQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{NkG5NUc,OjF7Mk[xPVE9N2F-
H441  M3nqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PncWlEPTB;MkG3NFAhdk1? M2nKZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUK2NVkyLz5{MUmyOlE6OTxxYU6=
H69 NH3RcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULDb4I1UUN3ME2yNFIxOCCwTR?= NX61TXpORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NlYyQTFpPkKxPVI3OTlzPD;hQi=>
PC3 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFyOECwJI5O NHG1PVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlE6OSd-MkG5NlYyQTF:L3G+
MTC-TT M1Gzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TXfGlEPTB;MD6wOEAsKDBwMEOg{txO M2LQRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPVk2Lz5{MUS3NFk6PTxxYU6=
MZ-CRC NGe3fINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPX[IN[UUN3ME6gOUDPxE1? NUnNc|h3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O|A6QTVpPkKxOFcxQTl3PD;hQi=>
TPC-1 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrNS4ZwUUN3ME2wMlA3KCtiMD6wNkDPxE1? NXfJUJdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O|A6QTVpPkKxOFcxQTl3PD;hQi=>
NIH-3T3/TPR-Met Ml7FSpVv[3Srb36gZZN{[Xl? Mo\yTY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iaX6gcY92e2ViTlnIMVNVOy:WUGKtUYV1KGOnbHzzMEBKSzVyIE2gNUDPxE1w NVvEOW8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVYyPDRpPkK0PVk3OTR2PD;hQi=>
BA/F3 NVfVSIRuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWnJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCYRVfGVlIhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdixiR1m1NEA:KDBwMECzJO69VS5? M{m5OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
BaF3 M1XXfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHX3e201QCCqcoO= NILMNZFKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDS[ZQhWzh7MVGgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLhSlMh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMD6wNUDPxE1w NELs[lc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
BA/F3 M17DXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2PTOVQ5KGi{cx?= NX7hS2ZNUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgWGVNNW[3c3XkJHJGXCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkC1JO69VS5? NUn3TXNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
TT MlXYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYHD[3RQOTBiZHH5dy=> M{PL[2lvcGmkaYTpc44hd2ZiUlXUJGM3OzSZIH31eIFvfCCrbjDoeY1idiCWVDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFExKGSjeYOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC5zMjFOwG0v NV;jXZp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
BA/F3 MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYrm[VJ5PDhiaILz NYrQe3h[UW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgVoV1KFZ6METNJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCwMlg6KM7:TT6= NUiwPW86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
BaF3 NUP6d29NT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVW0PEBpenN? MkDDTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHY5ODSOIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYV[zJINmdGy|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwOUGg{txONg>? NVHZ[29ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
Nthy-ori 3-1 MoPNR5l1d3SxeHnjbZR6KGG|c3H5 MWKxNEBl[Xm| NEWycmtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPfGi7LX;ybUA{NTFiY3XscJMh[W[2ZYKgNVAh\GG7czDifUBOXFRiYYPzZZktKEeLNUCgQUA1Njl|IN88UU4> NEe1bFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1Nlg3OCd-Mk[2OVI5PjB:L3G+
BAF3 M2HOUWZ2dmO2aX;uJIF{e2G7 NFrHWGkxNjBzIITvJFExKHWP NFfUb5gyKGi{ MWDJcohq[mm2aX;uJI9nKFSHTD3meZNm\CC5aXzkJJR6eGViUnX0JEh2dmuwb4fuJI9zcWerbjmgdIhwe3Cqb4L5cIF1cW:wIHH0JHkyODZ{L2m5NFUh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYYSgNE4xOSC2bzCxNEB2VSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? Mnf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT NFX1WlZHfW6ldHnvckBie3OjeR?= Ml;mOEBpenN? MWrJcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gVmVVKEN4M{TXJI12fGGwdDDheEB[QTB3IHnuJIh2dWGwIGTUJINmdGy|IHH0JFEhfU1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BAF3 MYPGeY5kfGmxbjDhd5NigQ>? NE[zbWMxNjBzIITvJFExKHWP NVnDNJAzOSCqch?= MnHvTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHM5QTGDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHCqb4PwbI9zgWyjdHnvckBifCC\MUC2Nk9[QTB3IHX4dJJme3OnZDDpckBud3W|ZTDCRWY{KGOnbHzzJIF1KDBwMEGgeI8hOTBidV2gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
BAF3 M1XYeWZ2dmO2aX;uJIF{e2G7 MlzlNE4xOSC2bzCxNEB2VQ>? NX\NWVhrOSCqch?= MmfLTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHM5QTGDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDQUGNo[W2vYTDheEB[Pzh|IHH0JFAvODFidH:gNVAhfU1iYX\0[ZIhOSCqcjDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NVz6TGVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI5PjBpPkK2OlUzQDZyPD;hQi=>
BAF3 MW\GeY5kfGmxbjDhd5NigQ>? M1X4VFAvODFidH:gNVAhfU1? NH3mc5UyKGi{ MnLvTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiUnX0JHM5QTGDIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDTbIMh[XRiWUOxO{BifCByLkCxJJRwKDFyIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz M2\S[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT MVXGeY5kfGmxbjDhd5NigQ>? M4r5WlEhfG9iMUCgeW0> M3P1WVQhcHK| NHWyS3JKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFzD[4FudWFicHjvd5Bpd3K7bHH0bY9vKGG2IGm3PFMh[XRiMTD0c{AyOCC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= M{ToclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT MW\GeY5kfGmxbjDhd5NigQ>? NX6x[JloOSC2bzCxNEB2VQ>? M3HwNVQhcHK| NFrlS4ZKdmirYnn0bY9vKG:oIGLFWEBEPjN2VzDteZRidnRiaX6gbJVu[W5iVGSgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiRWLLJJBpd3OyaH;yfYxifGmxbjDheEBVOjB{L2myNFQh[XRiMTD0c{AyOCC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= Ml\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT MUDGeY5kfGmxbjDhd5NigQ>? NUGzZ5pxOSC2bzCxNEB2VQ>? M1TKd|QhcHK| Ml\0TY5pcWKrdHnvckBw\iCURWSgR|Y{PFdibYX0ZY51KGmwIHj1cYFvKFSWIHPlcIx{KGG|c3Xzd4VlKGG|IIP1dJBz\XO|aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25iYYSgWFMxQC:VNEezJIF1KDFidH:gNVAhfU1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M1nnUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
TT NU\hWVBYTnWwY4Tpc44h[XO|YYm= NG\QT2syKHWP NHzLN3NKdmirYnn0bY9vKG:oIGLleE1lemm4ZX6gc45kd2enbnnjJJRz[W6|Zn;ycYF1cW:wIH;mJIh2dWGwIGTUJINmdGy|IHH0JFEhfU1iYomgd49nfCCjZ3HyJIF{e2G7 MkW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK4OlAoRjJ4NkWyPFYxRC:jPh?=
TT NVjrSHBSTnWwY4Tpc44h[XO|YYm= MU[xJJVO M2LETlQhcHK| MVLJcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gVmVVKEN4M{TXJI12fGGwdDDheEB[OTB4MjDpckBpfW2jbjDUWEBk\WyuczDheEAyKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3Mki2NEc,OjZ4NUK4OlA9N2F-
TT NXX2RVF1SXCxcITvd4l{KGG|c3H5 NI\vS3EyKHWP MXW5OkBpenN? M1rIS2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iVGSgZ4VtdHNiZYjwdoV{e2mwZzDS[ZQhSzZ|NGegcZV1[W62IHH0JFEhfU1iYX\0[ZIhQTZiaILzJIJ6KGGwbnX4bY5XN1CLIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpdy=> M3;XR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyPFYxLz5{Nk[1Nlg3ODxxYU6=
PC3 M3G5PWZ2dmO2aX;uJIF{e2G7 NXz1PWFKOSC2bzCzJIhzew>? NHXFdHhKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSzNiY3XscJMhcW6ldXLheIVlKG[xcjCxJJRwKDNiaILzMEBKSzVyIE2gNU46KM7:TT6= M1W3TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{G3NlAyLz5{NkexO|IxOTxxYU6=
MDA-MB-231 MoPzSpVv[3Srb36gZZN{[Xl? MY[xJJRwKDNiaILz M1PUc2lvcGmkaYTpc44hd2ZiQWjMJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOSC2bzCzJIhzeyxiSVO1NEA:KDVizszNMi=> M1z0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{G3NlAyLz5{NkexO|IxOTxxYU6=
BAF3 NHTqOHlHfW6ldHnvckBie3OjeR?= MlrYNUB1dyB|IHjydy=> MofLTY5pcWKrdHnvckBw\iCITGSzJEh2dmuwb4fuJI9zcWerbjmgdIhwe3Cqb4L5cIF1cW:wIITyZY5{\mWldHXkJIlvKG2xdYPlJGJCTjNiY3XscJMhcW6ldXLheIVlKG[xcjCxJJRwKDNiaILzMEBKSzVyIE2gO{42KM7:TT6= NIPyV5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkexO|IxOSd-Mk[3NVczODF:L3G+
MDA-MB-231 MWLGeY5kfGmxbjDhd5NigQ>? MoLyNUB1dyB|IHjydy=> MUHJcohq[mm2aX;uJI9nKEuLVDCoeY5sdm:5bjDvdolocW5rIIDoc5NxcG:{eXzheIlwdiC2cnHud4Zm[3SnZDDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhOSC2bzCzJIhzeyxiSVO1NEA:KDR{IN88UU4> NIPiTWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkexO|IxOSd-Mk[3NVczODF:L3G+
BA/F3 MYLGeY5kfGmxbjDhd5NigQ>? NVjJeIZIPDhiaILz NHuzb|BKdmirYnn0bY9vKG:oIFvEVkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFPlcIwhfGm2cnWg[4xwNWKjc3XkJIx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF2IN88UU4> NFzldmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki3OFc1OSd-Mk[4O|Q4PDF:L3G+
Sf21 MnK0SpVv[3Srb36gZZN{[Xl? NVuwWVgzOTVibXnudy=> MVzJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjpd{11[WepZXSgbJVu[W5iS1TSJIV5eHKnc4Pl[EBqdiCrboPlZ5QhW2Z{MTDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDJyIH3pcpMh[nliSGTSSkBie3OjeTygTWM2OCB;IECuNFE3KM7:TT6= M1PlSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe0O|QyLz5{Nki3OFc1OTxxYU6=
BA/F3 MUXGeY5kfGmxbjDhd5NigQ>? NYnLU4lFPDhiaILz MYLJcohq[mm2aX;uJI9nKEuLRkXCM3JGXCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JGNmdGxidHn0doUh\2yxLXLhd4VlKGy3bXnu[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMUmg{txONg>? M4XPVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe0O|QyLz5{Nki3OFc1OTxxYU6=
BA/F3 MnHpSpVv[3Srb36gZZN{[Xl? MkHDOFghcHK| MkLGTY5pcWKrdHnvckBw\iCNSV[1Rk9TTVRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlGvSlMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBE\WyuIITpeJJmKGeubz3iZZNm\CCudX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkG5JO69VS5? NV3KSVRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4O|Q4PDFpPkK2PFc1PzRzPD;hQi=>
BA/F3 NU\rWY5CSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NUD4XWlLPzJiaILz MmDJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJHRRWi2PZYSgZYZ1\XJiN{KgbJJ{KGK7IFPDT|gh[XO|YYmsJGlEPTBiPTCwMlAzOTlizszNMi=> NHjtTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2PFg5QSd-MkewOlg5QDl:L3G+
Sf21 NYq0NlNPTnWwY4Tpc44h[XO|YYm= Ml\ROlAhdWmwcx?= MlXBTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViTj30[ZJucW6jbDDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHJGXCBqNkW4JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoMkGgZ4VtdHNidYPpcocheG:ueTjHcJUtXHm{KUS6NUBieyC|dXLzeJJifGViaX7jeYJifGWmIH\vdkA3OCCvaX7zJIJ6KEWOSWPBMEBKSzVyIE2gNE4xODNizszNMi=> MnrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Sf21 M1;IVGZ2dmO2aX;uJIF{e2G7 NU[3WYNjPjBibXnudy=> NUDRVHF6UW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC22YXfn[YQhemWlb33ibY5idnRiaIXtZY4hWkWWIG[4NFROKG23dHHueEApPjV6IILld4llfWW|KTDlfJBz\XO|ZXSgbY4hcW6|ZXP0JHNnOjFiY3XscJMhfXOrbnegdI9tgSiJbIWsWJlzMTR8MTDhd{B{fWK|dILheIUhcW6ldXLheIVlKG[xcjC2NEBucW6|IHL5JGVNUVODLDDJR|UxKD1iMD64NVEh|ryPLh?= Mnq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
BaF3 NXjnXI86TnWwY4Tpc44h[XO|YYm= MYm3NkBpenN? NEfWdoJKdmirYnn0bY9vKG:oIFPDSGM3NVKHVDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCZWY{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLki4PUDPxE1w M1\PPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
BaF3 NVXwZZBzTnWwY4Tpc44h[XO|YYm= NVjsXGNMPzJiaILz MWHJcohq[mm2aX;uJI9nKEOFRFO2MXJGXCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYV[zJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjh6OTFOwG0v M3TLe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Ba/F3 M2DhOmZ2dmO2aX;uJIF{e2G7 Ml;uTY5pcWKrdHnvckBw\iCURWSgLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZpkhS2WubGTpeIVzNUeubzDseY1qdmW|Y3XuZ4Uh[XO|YYmsJGdKPTBiPTCwMlA4KM7:TT6= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzNEW2NEc,Ojd6MUS1OlA9N2F-
TT M2TzfGZ2dmO2aX;uJIF{e2G7 MoHGTY5pcWKrdHnvckBw\iCURWSgR|Y{PFdibYX0ZY51KGmwIHj1cYFvKFSWIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNlYh|ryPLh?= NY\p[HZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVQ2PjBpPkK3PFE1PTZyPD;hQi=>
Ba/F3 MkHsSpVv[3Srb36gZZN{[Xl? M{XtRmlvcGmkaYTpc44hd2ZiUlXUJHY5ODSPIH31eIFvfCBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLhM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W6lZTDhd5NigSxiR1m1NEA:KDBwN{Sg{txONg>? NH7P[ZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixOFU3OCd-Mke4NVQ2PjB:L3G+
Nthy-ori 3-1 M4O3XGN6fG:2b4jpZ4l1gSCjc4PhfS=> M4T3VmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG51cHlvb4LpJFMuOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwY3WgZZN{[XluIFfJOVAhRSB{LkmyJO69VS5? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzNEW2NEc,Ojd6MUS1OlA9N2F-
HepG2 M17QcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2jvO|czKGi{cx?= MoTiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6wNVIh|ryPLh?= NWPNToNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVIyPTlpPkK4OFEzOTV7PD;hQi=>
EBC1 M2rIfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MmTMO|IhcHK| M2POVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6wOVE1KM7:TT6= M{mxXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEGyNVU6Lz5{OESxNlE2QTxxYU6=
H1299 MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDjTYY4OiCqcoO= MljDS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTFEzQTliY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFEvQTF7IN88UU4> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
MCF7 M3PqUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV\GVopiPzJiaILz MmHBS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWNHPyClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gNk45QDlizszNMi=> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
A549 Mmn3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NG\zUGM4OiCqcoO= M3i5PWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFQvOjB3IN88UU4> Mn[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NUG5O|koRjJ6NkWxPVc6RC:jPh?=
T47D Mkj5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml[4O|IhcHK| Mo[3S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWFQ4TCClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyIE2gOE41PDhizszNMi=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
H460 M3T4O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYq3NkBpenN? NHHWZ2JIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJPDZyIHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA2NjZ4OTFOwG0v MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
HuH7 NEf4cZFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MlrDOFghcHK| MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDRwM{S4JO69VS5? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB3N{C0Nkc,OjlyNUewOFI9N2F-
A498 NIHud2lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MUC0PEBpenN? MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF2OUigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDhwNEW2JO69VS5? M3jkVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEW3NFQzLz5{OUC1O|A1OjxxYU6=
NCI-H727 NIfxTVRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{nPUFQ5KGi{cx?= M{HZcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg4OjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE1NjBzIN88UU4> NYXBVpg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwOVcxPDJpPkK5NFU4ODR{PD;hQi=>
BAF3 M3q5cWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NGTZOYE4OiCqcoO= NGf3RZVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJHRTWC2PRWSgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG|c3H5MEBKSzVyIE2gNE4xOjRizszNMi=> NUnoWZZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFY1PTJpPkK5NVQ3PDV{PD;hQi=>
A549 M1W2RWN6fG:2b4jpZ4l1gSCjc4PhfS=> M1XHPFExKHWP M4\uW|czKGi{cx?= M324XWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XRiMUCgeW0h[W[2ZYKgO|IhcHK|IHL5JGlv[3WleYTlJIxqfmVvY3XscEBqdWGpaX7nJIFv[Wy7c3nz Mn;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5OlMoRjJ7NEC3PVY{RC:jPh?=
A673 MnTvdWhVWyCjc4PhfS=> M1zHUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| M2fUXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY NGn6NY9yUFSVIHHzd4F6 MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NEDBNpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 M4jHVJFJXFNiYYPzZZk> MWPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NILGcYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 MlS2dWhVWyCjc4PhfS=> MkLUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| NG\3XWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MnrEdWhVWyCjc4PhfS=> NVX0T3g4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| NF\RRpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MnrJdWhVWyCjc4PhfS=> NUj5d3RqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NXewNWM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NGPIfnNyUFSVIHHzd4F6 M1X2VZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= NW\hXnNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 M375fZFJXFNiYYPzZZk> NX;u[XpqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NV3IWoFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M2XMepFJXFNiYYPzZZk> M4r1cZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NHjiNXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NYjINmlOeUiWUzDhd5NigQ>? MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NYK4ZVNHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 M3:2bJFJXFNiYYPzZZk> NGfiZVRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? MoPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS NI[0TmpyUFSVIHHzd4F6 MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM> Mn;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 M1[1TZFJXFNiYYPzZZk> NU\a[HlteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NETJbYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NEC2R2ZyUFSVIHHzd4F6 NHXwNWtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{ MmD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NUfKcXhmeUiWUzDhd5NigQ>? MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MlfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC Mm\IdWhVWyCjc4PhfS=> NEfMbGNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NVXuOIJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 NEjQflJyUFSVIHHzd4F6 M3XGO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz Mlf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 NYHzc3lveUiWUzDhd5NigQ>? M4ezdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= M4TwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 NGSwSWVyUFSVIHHzd4F6 NWLBd25neUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= M1TIdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 NH6ybopyUFSVIHHzd4F6 Mkj2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>? NW[5NIlNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 NIG0UnRyUFSVIHHzd4F6 M170U5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> NV74PVk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 NGWwb|FyUFSVIHHzd4F6 MmPCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{ MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
EBC1 MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NUH4TWoyPzJiaILz NGrDXmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFA1QCEQvF2u MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2OE[1OEc,OzB{NEi2OVQ9N2F-
MKN45 M3LOR2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVK2Z443PzJiaILz NWH6VGlvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNT241PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xODZ7IN88UU4> Mlr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{NEi2OVQoRjNyMkS4OlU1RC:jPh?=
SNU5 MVzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M{fDcFczKGi{cx?= MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOQVUWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEGyNUDPxE1w MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ2OE[1OEc,OzB{NEi2OVQ9N2F-
BAF3 NVnKfo46TnWwY4Tpc44h[XO|YYm= M2Hp[VczKGi{cx?= M{\yOGlvcGmkaYTpc44hd2ZiVGDSMZRi\2enZDDt[ZQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMUm4OkDPxE1w M363V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS4OlU1Lz5|MEK0PFY2PDxxYU6=
NCI-H460 MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3voNVczKGi{cx?= M{fnWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODRyMTFOwG0v NHLWdmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK0PFY2PCd-M{CyOFg3PTR:L3G+
MGHU3 MoLQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Mn;IO|IhcHK| MorORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPR1jVN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeR?= Mmm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|MEm2O|EoRjNyM{C5OlcyRC:jPh?=
RT112 NYXiVm1SSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NGLkfXE4OiCqcoO= NUnJboU2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSWFEyOiClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfS=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODNyOU[3NUc,OzB|MEm2O|E9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-MET(Y1234/1235) / MET / p-EGFR(Y1068) / EGFR / p-Gab1(Y627) / Gab1 / p-AKT(S473) / p-ERK / p-EIF4E; 

PubMed: 29188469     


MET kinase inhibitors but not emibetuzumab inhibited MET signaling pathway in Hs746t cells in vitro by western blot analysis. Hs746t cells were treated for 24 h with 133 nM (20 μg/ml) or 667 nM (100 μg/ml) emibetuzumab or MET kinase inhibitors (merestinib, PF04217903, crizotinib, cabozantinib) at 15.6, 62.5, 250 or 1000 nM.

p-MET / p-ERK / p-AKT; 

PubMed: 29520051     


Western blot analysis of cellular pathways modifications after CBZ 5 μM treatment in HOS, MG-63, Saos-2 and U-2 OS cells; (A) CBZ 5 μM inhibits c-MET phosphorilation after 1 hour of treatment; downstream ERK activation kinetic adopts a sigmoidal shape in all OS cell lines, whereas AKT activation is strongly inhibited in HOS, Saos-2 and U-2OS, but not in MG-63 cells.

29188469 29520051
Immunofluorescence
α-tubulin; 

PubMed: 29520051     


Immunostaining of mitotic spindle in control and CBZ 5 μM treated HOS cells using a monoclonal antibody against α-tubulin (in green); white arrows indicate the mitotic spindle poles; control cells show normal bipolar spindles during metaphase formation, whereas treated cells show tripolar spindles during prometaphase (II), metaphase (III) and anaphase (IV); bar scale = 10 μm.

29520051
Growth inhibition assay
Cell viability; 

PubMed: 23661005     


Cells were left untreated or were treated with 5, 7.5 or 10 μM cabozantinib (XL184). Seventy-two hours later viability was detected by MTT-assay and apoptosis by staining with annexinV-FITC followed by FACS-analysis.

23661005
In vivo XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. [1] XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]

Protocol

Cell Research:

[2]

- Collapse
  • Cell lines: ST88-14, STS26T, and MPNST724
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 48 hours
  • Method:

    Cells are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: RIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
  • Dosages: ~60 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (199.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 501.51
Formula

C28H24FN3O5

CAS No. 849217-68-1
Storage powder
in solvent
Synonyms XL184
Smiles COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04631744 Not yet recruiting Drug: Cabozantinib Prostate Cancer Weill Medical College of Cornell University|Exelixis February 15 2021 Phase 2
NCT04551430 Not yet recruiting Drug: Cabozantinib|Drug: Nivolumab|Drug: Ipilimumab Metastatic Soft-tissue Sarcoma Washington University School of Medicine|Exelixis|Bristol-Myers Squibb December 31 2020 Phase 2
NCT04524208 Not yet recruiting Drug: Cabozantinib Neuroendocrine Tumors|Neuroendocrine Carcinoma Karsten Gavenis|University Medical Center Goettingen December 1 2020 Phase 2
NCT04300140 Recruiting Drug: AVB-S6-500|Drug: Cabozantinib (Cabo) Clear Cell Renal Cell Carcinoma Aravive Inc. December 2020 Phase 1|Phase 2
NCT04637204 Recruiting Drug: Cabozantinib|Drug: Axitinib Renal Cell Carcinoma Ipsen November 24 2020 --
NCT04609800 Withdrawn -- Renal Cell Carcinoma Ipsen November 6 2020 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) supplier | purchase Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) cost | Cabozantinib (BMS-907351) manufacturer | order Cabozantinib (BMS-907351) | Cabozantinib (BMS-907351) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID